RxSight
David Dibble is a Senior Synthetic Organic Chemist at RxSight, Inc., specializing in the development of new small molecule and macromolecular components for next-generation intraocular lenses to enhance lens performance. Previously, David served as a Senior Bioconjugation Chemist at Abbott, where responsibilities included preparing conjugates for drug testing kits and contributing to process enhancements for manufacturing capacity. At Zymo Research Corp, David reformulated nucleic acid purification and size selection kits for next-generation sequencing, focusing on stability and user handling improvements. Prior experience includes working as a Research and Development Chemist at Lacamas Laboratories and as an Associate Specialist at UC Irvine's Blum Research Group, investigating polymerization mechanisms. David holds a Ph.D. in Chemistry from UC Irvine and a B.S. in Chemistry from the University of California, Santa Cruz.
This person is not in any teams
This person is not in any offices
RxSight
1 followers
RxSight® is a privately-held corporation headquartered in Aliso Viejo, California that has commercialized the world’s first and only adjustable intraocular lens (IOL) that is customized after cataract surgery. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye.